38980-96-0

Usage

Uses

Used in Research and Pharmaceutical Settings:
4-Trifluoromethyl-Benzamidine HCl is used as a potent inhibitor of serine proteases for the study of proteolytic enzymes. Its ability to inhibit these enzymes aids in understanding their role in various biological processes and diseases.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-Trifluoromethyl-Benzamidine HCl is used as a reagent, leveraging its unique chemical properties to facilitate specific reactions and the creation of desired compounds.
Used in Drug Development:
4-Trifluoromethyl-Benzamidine HCl is utilized in drug development as a lead compound or a structural component in the design of new pharmaceuticals targeting serine protease-related conditions.
Used in Analytical Chemistry:
4-TRIFLUOROMETHYL-BENZAMIDINE HCL can be employed in analytical chemistry as a standard or a reference material for the development and validation of assays and methods for the detection and quantification of serine proteases or related compounds.
It is important to handle and use 4-Trifluoromethyl-Benzamidine HCl with appropriate safety precautions due to its reactivity and potential hazards.

InChI:InChI=1/C7H6Cl2N2/c8-4-2-1-3-5(9)6(4)7(10)11/h1-3H,(H3,10,11)

Upstream product

• 455-18-5 4-CF₃C₆H₄CN 
• 56108-08-8 4-Trifluoromethyl-benzimidic acid methyl ester; hydrochloride 
• 22179-86-8 4-(trifluoromethyl)benzamidoxime 

Downstream Products

• 115127-52-1 3-chloro-3-(4-trifluoromethylphenyl)diaziridine 
• 95911-64-1 3-(p-(trifluoromethyl)phenyl)diazirine 
• 898562-57-7 C₈H₆ClF₃N₂ 
• 898562-59-9 C₈H₄Cl₃F₃N₂ 
• 851069-61-9 4-methyl-2-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 762286-20-4 methyl 2-(4-(trifluoromethyl)phenyl)imidazole-5-carboxylate 
• 851069-67-5 4-cyclopropyl-2-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 851069-56-2 4-(2-methoxy-ethyl)-2-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 851070-18-3 4-(2-methoxy-ethyl)-6-methyl-2-(4-trifluoromethyl-phenyl)-pyrimidine-5-carboxylic acid methyl ester 
• 466664-93-7 [2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methanol 
• 180606-37-5 6-Hydroxy-2-(4'-trifluoromethylphenyl)-4-pyrimidinone 
• 180606-38-6 5-Methoxy-2-(4'-trifluoromethylphenyl)-4-pyrimidinone 
• 1208259-10-2 2-(4-(trifluoromethyl)phenyl)quinazoline 
• 1240313-23-8 6-ethoxycarbonyl-4-hydroxy-5-methyl-2-(4-trifluoromethylphenyl)-pyrimidine 

Relevant academic research and scientific papers

Silver-catalyzed [3+2+1] annulation of aryl amidines with benzyl isocyanide

A silver-catalyzed [3+2+1] annulation of amidines with benzyl isocyanide toward 2,4-diaryl-1,3,5-triazines was developed. A variety of symmetrical and unsymmetrical products were obtained in moderate to good yields. This work also features an oxidant-free approach to 2,4-disubstituted triazines.

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Preparation of amidines from amidoximes via transfer hydrogenation

Amidoximes are reduced into amidine using triethyl silane and PdCl 2 in acetic acid. Copyright

Amino piperidine derivatives

The invention comprises novel aminopiperidine derivatives, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I prevent the human immunodeficiency virus (HIV) from entering cells by blocking interaction of the viral envelope protein gp120 with a chemokine receptor on the cell surface. The compounds of this invention may be advantageously used as therapeutic agents for the treatment of diseases mediated by the human immunodeficiency virus (HIV), either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers.

Thienyloxypyridines and-pyrimidines useful as herbicidal agents

The present invention provides a herbicidal compound of formula I, methods for the preparation thereof and intermediates useful therefor. wherein X and Y are each independently O or S; Z is N or CR4.

Heterocyclic derivatives in the treatment of Ischaemia and related diseases

Compounds of the formula: STR1 wherein A, R1, R2, R3 and m are defined as in the specification or a pharmaceutically acceptable acid addition salt or N-oxide thereof, are calcium and sodium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and also for treatment of spinal injuries.

Preparation of Triazolopyrimidines as Potential Antiasthma Agents

With the use of the human basophil histamine release assay, 5-aryl-2-aminotriazolopyrimidines were found to be active as mediator release inhibitors.These compounds were prepared by reacting arylamidines with sodium ethyl formylacetate or with ethyl propiolate to give pyrimidinones.Treatment with phosphorus oxychloride gave a chloropyrimidine, which was converted to a hydrazinopyrimidine with hydrazine.Cyclization, using cyanogen bromide, gave the triazolopyrimidines, after a Dimroth rearrangement.Following a structure-activity evaluation, the5--2-amino (8-10), 5-(3-bromophenyl)-2-amino (8-13), 5--2-amino (8-11), and 5-(4-pyridinyl)-2-amino (6-7) compounds were found to have the best activity.They were chosen for further pharmacological and toxicological study.

AZIDE AND FLUORIDE EXCHANGE REACTIONS OF HALODIAZIRINES

Reactions of 3-aryl-3-bromodiazirines (11) with molten tetrabutylammonium fluoride at 25degC provide 65-74percent isolated vields of the novel corresponding 3-aryl-3-fluorodiazirines (12) Related reactions of 11 with tetrabutylammonium azide afford high yields of aryl nitriles.The latter reactions are believed to proceed through unstable intermediate 3-aryl-3-azidodiazirines (7).These reactions involve rate-determining formation of 7 and display kinetics which are first order in azide ion and bromodiazirine.The likely intermediacy of aryldiazirinium bromide ion pair between 11 and 7 is supported by a combination of salt effect, leaving group effect and Hammett studies.Molecular orbital calculations are employed to characterize azidodiazirines as well as the mode of their decomposition to nitriles.In particular, we consider the possible itermediacy of a 3-nitrenodiazirine or an azidocarbene.